Myriad Genetics Q1 2024 Adj EPS $(0.01) Beats $(0.10) Estimate, Sales $202.200M Beat $193.506M Estimate
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics (NASDAQ:MYGN) reported Q1 2024 adjusted EPS of $(0.01), beating the $(0.10) estimate, with sales of $202.200M surpassing the $193.506M estimate. This represents a significant improvement over the previous year's losses and sales figures.
May 07, 2024 | 9:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics reported a smaller loss than expected and higher sales for Q1 2024, indicating a strong performance compared to the same period last year.
The positive earnings surprise and sales beat by Myriad Genetics suggest a strong operational performance, likely leading to increased investor confidence and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100